Lectures

Establishes the rationale for exercise as medicine, anchored in epidemiological evidence and the claim that physical activity rivals or exceeds pharmacological. Establishes the rationale for exercise as medicine, anchored in epidemiological evidence and the claim that physical activity rivals or exceeds pharmacological interventions across major disease domains. Introduces the MoTrPAC consortium's multi-omic endurance training atlas, illustrating the scale and tissue-specificity of exercise-induced adaptation across molecular platforms, sexes, and time points. Contextualises leading causes of death in the USA and Germany to demonstrate that the diseases most amenable to exercise intervention are precisely those dominating population mortality. Outlines the structure of the lecture series, framing subsequent topics — exerkines, metabolic disease, prescription methodology, anti-inflammatory effects — as applications of a unified conceptual model.

Frames sleep as an active, quantifiable performance reserve with dose-response effects on strength, glucose tolerance and immune function. Frames sleep as an active, quantifiable performance reserve with dose-response effects on strength, glucose tolerance and immune function. Situates the circadian system — from the SCN pacemaker to peripheral muscle oscillators — as a regulatory layer that exercise can entrain or disrupt depending on timing. Presents Saner et al.'s finding that acute sleep restriction impairs mitochondrial respiration, glucose tolerance and muscle protein synthesis. Demonstrates that a structured HIIE protocol can partially rescue these deficits, while emphasising that exercise serves as mitigation rather than a substitute for sleep, with distinct implications for athletes and clinical populations.

Defines exerkines as exercise-induced signalling molecules acting across autocrine, paracrine and endocrine pathways, originating from multiple tissues beyond skeletal muscle. Reframes muscle-derived IL-6 as an energy allocator — sensing glycogen depletion, liberating hepatic and adipose fuel, and enhancing insulin sensitivity — distinct from its pro-inflammatory role in infection. Describes the stereotyped three-phase cytokine cascade of acute exercise and the anti-inflammatory basal shift induced by chronic training. Highlights Ringleb et al.'s finding that myokine and extracellular vesicle responses to endurance exercise differ meaningfully by sex and age, underscoring the need for personalised prescription in older adults.

Frames prediabetes as an active cardiometabolic risk state rather than a benign waiting period, emphasising physical inactivity as a primary driver through reduced GLUT4 translocation, visceral adiposity and low-grade inflammation. Introduces continuous glucose monitoring as a teaching tool for illustrating postprandial dynamics, counter-regulatory hormone responses and the acute glucose-lowering effect of exercise. Explains the dual insulin- and contraction-mediated GLUT4 pathways, highlighting that the contraction-mediated route remains functional in insulin-resistant muscle and forms the molecular rationale for exercise prescription. Distinguishes obese phenotypes by visceral fat and insulin sensitivity rather than BMI alone, and presents waist circumference as a practical frontline diagnostic for cardiometabolic risk stratification.

Defines the metabolic syndrome as a clinically meaningful cluster of cardiometabolic risk factors addressable simultaneously by exercise, and positions cardiorespiratory fitness as a routine vital sign with stronger prognostic value than BMI alone. Presents Sandforth et al.'s finding that VAT reduction — rather than weight loss per se — is the strongest predictor of prediabetes remission, mediated through improved insulin sensitivity and ectopic fat clearance. Introduces the Dunstan framework showing that breaking up sedentary time confers cardiovascular benefit partially independent of structured exercise, with short activity interruptions meaningfully reducing postprandial glucose. Outlines a five-step clinical pathway from risk diagnosis through CRF estimation and VAT quantification to structured exercise prescription and follow-up.

Defines exercise snacks as brief, vigorous, periodically distributed activity bouts of under one minute, positioned as a dose-conserving alternative for individuals unable to complete structured exercise sessions. Presents laboratory and real-world evidence showing measurable improvements in V̇O₂peak, postprandial glucose and insulin sensitivity, with stair climbing highlighted as a practically accessible modality. Introduces Stamatakis et al.'s finding that as little as one to two minutes of vigorous intermittent activity three times daily is associated with roughly 40–50% reductions in all-cause, cancer and cardiovascular mortality. Discusses meal-timed exercise snacks as a targeted intervention against postprandial glycaemic excursions via acute GLUT4 translocation and sustained insulin sensitivity, and outlines a practical counselling and workplace implementation framework.

Establishes the clinical and economic rationale for exercise prescription in non-communicable disease, noting that 31% of adults and 81% of adolescents fail to meet WHO activity recommendations. Presents the DDG-Praxisempfehlung framework for diabetes, combining aerobic training, resistance training, flexibility work and sedentary-time reduction, with specific attention to glycaemic monitoring and hypoglycaemia risk in insulin-treated patients. Introduces the four principal intensity-prescription anchors — %HRR, %HRmax, RPE and METs — detailing their respective strengths, limitations and clinical indications. Addresses the distinct metabolic challenges of type 1 diabetes, including GLUT4 resequestration under insulin deficiency and the divergent glucose responses to aerobic versus anaerobic exercise, and outlines a structured clinical pathway from patient stratification to outcome review.

Distinguishes the acute transient pro-inflammatory response to exercise from the net anti-inflammatory effect of chronic training, framing both through the exerkine cascade — particularly TNF-α-independent IL-6 signalling — and its kinetic sequence across 24–72 hours. Presents Gleeson et al.'s integrative model linking visceral adiposity reduction, adipokine rebalancing and macrophage phenotype shifts as the dominant mechanisms of exercise-induced chronic anti-inflammation, with diet acting additively. Describes the biphasic immune cell response to acute exercise — catecholamine-driven lymphocytosis followed by cortisol-mediated lymphopenia — as a physiological surveillance mechanism with cumulative immunological training effects. Highlights NK cells as the most exercise-sensitive lymphocyte subset, connecting their acute mobilisation and chronic adaptation to reduced infection susceptibility and anti-tumour immune surveillance.

Reframes NAFLD as MAFLD to reflect its identity as a hepatic manifestation of systemic metabolic dysfunction, and maps the disease spectrum from simple steatosis through fibrosis to cirrhosis. Explains the mechanisms by which HIIT reduces hepatic fat — enhanced fatty acid oxidation via PGC-1α, PPAR-α and AMPK, reduced de novo lipogenesis, and indirect adipose-mediated signalling — alongside anti-inflammatory Kupffer cell phenotype shifts. Presents the 4×4 HIIT protocol as the best-evidenced exercise prescription for MAFLD, with documented improvements in liver fat, ALT, insulin sensitivity and V̇O₂max, and outlines practical screening and progression considerations. Introduces protein-adequate dietary patterns as a complementary intervention supporting muscle mass and hepatic regeneration, and summarises the ESSA position statement endorsing aerobic exercise, resistance training and sedentary-time reduction as first-line lifestyle management.

Frames IBD as a chronic immune-dysregulation disease in which disrupted mucosal barrier function, Th1/Th17 dominance and microbiota cross-talk create a therapeutic opening for exercise. Presents Jones et al.'s meta-analytic evidence that structured exercise reduces disease activity scores and reliably improves fatigue, psychological wellbeing and physical function, mediated through exerkine signalling, SCFA-producing microbiome shifts, vagal tone enhancement and visceral fat reduction. Distinguishes the acute immune signatures of MICT, HIIT and resistance training, and maps appropriate exercise modality to disease state — from light walking during flares to combined HIIT and resistance training in established remission. Highlights the clinical significance of SCFA-fatigue and TNF-α-quality-of-life correlations, and introduces a 13-component pathway model underwriting multimodal exercise prescription as a disease-modifying behaviour in IBD.

Establishes the disease-state-specific prescription principle for IBD, distinguishing flare, moderate remission and established remission as three distinct clinical contexts requiring different exercise doses. Presents operational prescriptions for each state — from brief light walking at low intensity during flares, through moderate continuous cycling, to vigorous 8×30-second interval blocks in established remission — with practical notes on modality, accumulation and symptom monitoring. Outlines a worked weekly programme architecture for both stable remission and flare recovery, and defines progression rules based on duration-before-intensity sequencing and a 10% weekly volume cap. Provides a five-step decision algorithm integrating disease activity, fitness baseline, and patient readiness to guide prescription selection, progression and de-escalation.

Synthesises the exerkine framework as the connective biology of the entire lecture series, positioning skeletal muscle as the central signalling hub communicating with liver, adipose tissue, brain, gut, bone and immune system through endocrine, paracrine and extracellular vesicle pathways. Contrasts the transient exerkine pulse of a single exercise bout with the chronic baseline reshaping produced by regular training, linking both to the clinical outcomes addressed across Lectures 4–11. Highlights that pharmacological mimicry of individual exerkines cannot replicate the coordinated, pulsatile, multi-organ network activated by exercise, reinforcing the opening premise of the series. Identifies active translational frontiers — exerkine biomarker panels for personalised prescription, EV cargo as dose verification, and age-related signalling decline — and closes with the clinical principle that exercise prescription is personalised, multimodal and integrated with diet and sleep.